FNDC5/Irisin inhibits pathological cardiac hypertrophy

Yu, Q; Kou, WX; Xu, X; Zhou, SP; Luan, PP; Xu, XP; Li, HL; Zhuang, JH; Wang, J; Zhao, YF; Xu, YW; Peng, WH

Zhao, YF; Xu, YW; Peng, WH (reprint author), Tongji Univ, Sch Med, Dept Cardiol, Shanghai Peoples Hosp 10, Shanghai, Peoples R China.

CLINICAL SCIENCE, 2019; 133 (5): 611

Abstract

Cardiac hypertrophy is a common pathophysiological process in various cardiovascular diseases, which still has no effective therapies. Irisin is a nov......

Full Text Link